In the past 12 hours, Boston-area and national tech coverage skewed toward practical applications of AI and data—alongside a steady stream of life-sciences and infrastructure announcements. The Coalition for Secure AI (CoSAI) used RSAC 2026 as a springboard to publish two new research papers focused on “agentic identity and access management” and the broader shift from chatbots to autonomous “swarms,” framing agent security as an enterprise identity/access problem as much as a technical one. In healthcare, WBUR reported early Massachusetts patient experiences with AI breast-cancer risk detection from mammogram images, emphasizing that adoption depends on research, guidelines, insurance rules, and rollout costs. Other AI-adjacent business news included Aptia adding FitOn Health to its employer well-being ecosystem and Novem deploying Creatio’s agentic CRM/workflow platform across five Mexico branches in six weeks.
Infrastructure and operational technology also featured prominently. Utah Broadband announced a nearly $23M USDA ReConnect award to build 315 miles of fiber-to-the-premises network delivering symmetrical 10/10 Gbps service to 3,000+ homes and businesses in northern Utah. Boston-based Transaera (via TechCrunch) highlighted a ventilation unit designed to pull moisture from indoor air so HVAC systems don’t need to overcool and reheat—citing Amazon’s multi-year deal after testing in Houston. In enterprise software, Novem’s Creatio rollout was positioned as a rapid move from fragmented tools and manual processes to centralized pipeline and customer/project visibility.
Life sciences and biotech dealflow continued, with several items that look more like routine corporate updates than single “breakthrough” moments—but collectively they show sustained momentum. CellCentric completed an oversubscribed $220M Series D to advance its oral p300/CBP inhibitor in multiple myeloma, including Phase 2 DOMMINO-1 enrollment and Phase 3 DOMMINO-2 planning. GSK’s $55M upfront deal with China’s SiranBio targets ALK7 via an oligonucleotide (SA030) for cardiometabolic disease, while Unravel Biosciences published the first Spanish-language linguistic validation of the Rett Syndrome Behavioral Questionnaire to broaden clinical research use. Separately, Immusoft announced a poster presentation in Boston for engineered B-cell therapy data in MPS I, and Starfish Storage won a Bio-IT World award for turning a 20-year CT archive into live research infrastructure with Arizona State University.
Taken together, the most “significant” thread in the last 12 hours is the growing focus on agentic AI security and governance—supported by CoSAI’s RSAC-linked research release—while the rest of the coverage is more fragmented across healthcare adoption, enterprise tooling, and biotech financing/updates. Older material in the 12–72 hour window reinforces continuity in AI and enterprise themes (e.g., IBM/Aramco AI collaboration and broader AI adoption concerns), but the evidence base for a single, major Boston-specific technology shift is strongest only in the CoSAI agent-security item and the Massachusetts AI breast-cancer adoption story.